Modern approaches to the treatment of patients with chronic hepatitis B
Abstract
The aim of review. To present up-to-date references, that allows to choose the optimal mode of antiviral therapy for patient with chronic hepatitis B (CHB).
Original positions. Chronic HBV-infection represents a major epidemiologic and economic problem all over the world. Liver cirrhosis (LC) and hepatocellular carcinoma (HCC) related to HBV infection are the causes for over 1 million deaths and 5–10% of transplantations of liver per year. The comprehension of the role of viral load in development of LC and HCC and introduction to the pharmaceutical market of new agents allow to improve guidelines on management of patients with chronic HBV-infection. The main criterion of efficacy of antiviral therapy (AVT) – the level of viral load. Monitoring of HBV DNA on the 12, 24, 48-th weeks of treatment enables to predict its efficacy and risk of development of resistance to nucleoside/nucleotides analogues. It is recommended to consider patients with CHB with viral load of over 2000 МЕ/ml (≈10000 copies/ml) and/ or elevation of alanineaminotransferase (ALT) activity, with signs of moderate to severe inflammatory-necrotic changes and/or liver fibrosis as candidates for AVT. Patients with LC are considered as candidates for AVT even at normal ALT levels irrespective of level of viral load. For decompensated LC patients nucleoside/ nucleotides analogues are the drugs of choice. New analogues nucleoside/nucleotides (telbivudine, entecavir, tenofovir) have direct antiviral action and good tolerability at long application.
Conclusion. Modern international references on management of patients with HBV-infection allows to increase efficacy of treatment by of rational application of antiviral agents, to improve survival rate, to reduce mortality and risk of LC and HCC development, to optimize treatment cost.
About the Authors
S. F. GalimovaRussian Federation
M. V. Mayevskaya
Russian Federation
V. T. Ivashkin
Russian Federation
References
1. Blumberg B.S., Alter H.J. et al. A «new» antigen in leukemia sera // JAMA. – 1965. – Vol. 191. – P. 541.
2. Chang T.T., Gish R.G., de Man R. et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B // N. Engl. J. Med. – 2006. – Vol. 354. – P. 1001–1010.
3. Chien-Jen Sc.D., Hwai-I. Yang, MSc et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level // JAMA. – Jan 4. – 2006.
4. EASL Clinical Practice Guidelines: Management of chronic hepatitis B // J. Hepatol. – 50 (2009), doi: 10.1016/j.lhep.2008.10.001.
5. Fournier C., Zoulim F. Antiviral therapy of chronic hepatitis B: prevention of drug resistance // Clin. Liver Dis. – 2007. – Vol. 11. – P. 869–892.
6. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J. et al. Long-term therapy with adefovie dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years // Gastroenterology. – 2006. – Vol. 131. – P. 1743–1751.
7. Heathcote E.J., Gane E., Deman R. et al. A randomized double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for treatment of HBeAg positive chronic hepatitis B (CHB): Study GS-US-174-0103 // Hepatology. – 2007. – Vol. 46. – P. 861.
8. Hoofnagle J.H., Doo E., Liang T.J. Management of hepatitis B: summary of a clinical research workshop // Hepatology. – 2007. – Vol. 45. – P. 1056–1075.
9. Janssen H.L., van Zonneveld M., Senturk H. et al. Pegilated interferon alfa 2b alone or in combination with lamivudinefor HbeAg-positive chronic hepatitis B: a randomized trial // Lancet. – 2005. – Vol. 365. – P. 123–129.
10. Keeffe E.B., Zeuzem S., Koff R.S. et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B // Clin. Gastroenterol. Hepatol. – 2007. – Vol. 5. – P. 890–897
11. Lai C.L., Chien R.N., Leung N.W. et al. A one-year trial of lamivudine for chronic hepatitis B // N. Engl. J. Med. – 1998. – Vol. 339. – P. 61–68.
12. Lai C.L., Gane E., Liaw Y.F. et al. Telbivudine versus lamivudine in patients with chronic hepatitis B // N. Engl. J. Med. – 2007. – Vol. 357. – P. 2576–2588.
13. Lai C.L., Shuoval D., Lok A.S. et al. Entecavir versus lamivudine for patients with HbeAg-negative chronic hepatitis B // N. Engl. J. Med. – 2006. – Vol. 354. – P. 1011–1020.
14. Lok A.S., Hussain M. et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management // Hepatology. – 2007. – Vol. 46. – P. 254–265.
15. Lok A.S., McMahon B.J. AASLD practice guidelines. Chronic hepatitis B // Hepatology. – 2007. – Vol. 45. – P. 507–539.
16. Marcellin P., Buti M., Krastev Z. et al. A randomized double-blind, comparison of tenofovir DF versus adefovir dipivoxil for the treatment of HBeAg negative chronic hepatitis B: Study GS-US-174-0102 // Hepatology. – 2007. – Vol. 46. – P. 290–291.
17. Marcellin P., Chang T.T., Lim S.G. et al. Adefovir dipivoxil for treatment of hepatitis B e-antigen positive chronic hepatitis B // N. Engl. J. Med. – 2003. – Vol. 348. – P. 808–816.
18. Marcellin P., Jacobson I., Habersetzer F. et al. Tenofovir disoproxil fumarate for the treatment of HBeAg-negative chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch data (study 102) // J. Hepatol. – 2008. – Vol. 48 (suppl. 2). – P. 26.
19. Marcellin P., Lau G.K., Bonino F. et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B // N. Engl. J. Med. – 2004. – Vol. 351. – P. 1206–1217.
20. Pawlotsky J.M., Dusheiko G., Hatzakis A. et al. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach // Gastroenterology. – 2008. – Vol. 134. – P. 405–415.
21. Uchenna H. Iloeje, Hwai-I. Yang et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load // Gastroenterology. – 2006. – Vol. 130, N 3.
Review
For citations:
Galimova S.F., Mayevskaya M.V., Ivashkin V.T. Modern approaches to the treatment of patients with chronic hepatitis B. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2009;19(3):13-20. (In Russ.)
Views:
7
Email this article 
